Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Frontiers in ImmunologyOpen Access

Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYulin WangSWShuang WuYWY L Wei

Discussion

Loading...

Member takes

Overview

Meta-analysis assesses circulating tumor DNA as a prognostic indicator for survival in advanced NSCLC patients receiving immune checkpoint inhibitors, suggesting personalized treatment strategies.

Key Points

  • The analysis aims to evaluate the prognostic significance of circulating tumor DNA (ctDNA) in predicting survival outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
  • Systematic review of 31 studies with 2,107 patients from multiple databases.
  • Cochrane RoB-2 and Newcastle-Ottawa Scale used to assess study quality.
  • Hazard ratios and 95% confidence intervals pooled using random/fixed-effects models.
  • Patients with undetectable ctDNA at baseline had prolonged PFS (HR = 0.49, 95% CI: 0.34–0.70, P < 0.01) and OS (HR = 0.45, 95% CI: 0.32–0.65, P < 0.01).
  • ctDNA reduction during treatment significantly improved PFS (HR = 0.27, 95% CI: 0.21–0.35, P < 0.01) and OS (HR = 0.23, 95% CI: 0.17–0.31, P < 0.01).
  • Complete molecular response showed the strongest predictive power for PFS (HR = 0.27, 95% CI: 0.18–0.41, P < 0.01) and OS (HR = 0.19, 95% CI: 0.12–0.29, P < 0.01).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf2a9faef96ed7f0556fchttps://doi.org/10.3389/fimmu.2026.1812209
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis2026
  2. 2Early circulating tumor DNA dynamics as a prognostic and predictive biomarker in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis.2026
  3. 3Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers2025
  4. 4Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers2025
  5. 5Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy2024 · 18 citations